200 SIDNEY STREET, CAMBRIDGE, MA
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Executive Appointments - Richard Kender Named Interim CEO at Seres Therapeutics
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Other Events
Reports Second Quarter 2025 Financial Results and Provides Business Updates
Changes in Board, Management or Compensation
Reports First Quarter 2025 Financial Results and Provides Business Updates
News, Articles of Incorporation
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Definitive Merger Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
PREM14A